Oct 15, 2019
The Equine Medical Research Fund was created in 2014 to provide consistent funding for equine medical research, which has historically been underfunded. A $1.00 starter fee was added to each USEA recognized event entry beginning in 2014, and at years end a majority of those dollars were distributed through the Morris Animal Foundation, which assists the USEA with selecting studies to fund, monitoring the funds, and reporting on progress. Morris has decades of experience in reviewing grant applications from universities and research institutions and has a team of veterinarians who spend thousands of volunteer hours assessing which studies are most likely to impact horse welfare. Ultimately, a committee from the USEA comprised of riders and veterinarians will determine which studies the USEA dollars will target.
This years committee recommendation is a bit different as the committee is recommending spreading funds among three entities - the Stephen Teichman Farrier study, a Grayson Jockey Club Research Foundation study, and two Morris Animal Foundation Studies.
Through these partnerships, the USEA is helping to address the major problem of equine research underfunding while maintaining control over how member dollars are distributed. Although the committee is always interested in recommending studies that concern general horse welfare, this year we took a closer look at recommending studies that were geared to solving issues that concern performance horses. The goal of our selection philosophy is to provide USEA positive PR through funding a variety of institutions and studies that show our support for horse care, welfare, and rehabilitation.
In 2017, $46,900 dollars were distributed between five different studies on different topics pertaining to equine health, from improving regenerative therapies to studying gaps in the equine genome related to tendon health.
In 2018, $44,858 dollars were distributed between four different studies on a variety of topics including insulin's relation to laminitis, stem cell therapies, equine asthma, and joint infections.
At the USEA Board of Governors meeting in August, the Equine Medical Research Committee recommended the funding of four studies using the $39,581 collected in 2018 and the Board approved their recommendation. Below are additional details about the four selected studies.
Non-Invasive Evaluation of Host-Microbiota Interactions Canaan Whitfield-Cargile, Texas A&M
Summary: This study aims to develop a non-invasive platform to serve as a diagnostic test for gastrointestinal inflammation prior to severe disease and to reveal how bacteria in the gut influence horse health.
Description: One of the most important and common classes of diseases affecting horses are gastrointestinal (GI) diseases including colic and colitis. Despite tremendous research efforts to both diagnose and prevent these diseases, they remain very common and frequently are not diagnosed until severe disease is present. One area that is gaining recognition as an important player in equine GI health and disease is GI bacteria or the microbiota. The microbiota consists of all of the bacteria and other microorganisms in the GI tract. Alterations in the amounts and types organisms that make up the microbiota have been linked to both GI and non-GI diseases of horses including colic, colitis, laminitis, and obesity. These findings are part of the reason why there are a vast array of prebiotics, probiotics, and other products on the market that claim to influence the GI microbiota. Unfortunately, there is minimal evidence to support the efficacy of these products and a lack of understanding of how these products work. A major contributor to the lack of evidence and understanding of these products is related to an inability to monitor the health and function of the equine GI tract. It is clear when severe disease is present but currently impossible to monitor subtle changes. Similarly, while we can easily diagnose severe inflammation and microbiota changes during disease, we cannot capture the changes that occurred prior to clinical disease. These limitations result in capturing results of GI injury and disease but not causes. Consequently, there is great need for improved understanding of the causes of disease and early identification of horses at-risk of developing GI disease. In the absence of such knowledge, effective intervention strategies to reduce GI and GI-related health risks will remain elusive.
Horses and other animals naturally shed cells lining the GI tract on a daily basis. People, in fact, shed up to 1/3 of the cells lining their GI tract daily. We have developed a technique for examining the gene expression profile of these cells to monitor the health and function of the GI tract from fecal samples. We have shown that this approach offers a promising means to non-invasively examine the response of the GI intestinal tract to injury. Further, we have convincing preliminary data demonstrating that the gene expression profile arising from these cells mirrors the gene expression profile of the tissues within the GI tract of the horse and provides a global view of the health and function of the GI tract. This approach offers a highly attractive, non-invasive means of monitoring GI responsiveness to disease and interventions. Thus, our long-term goals are to 1) develop inexpensive, non-invasive diagnostic tests in order to document GI inflammation prior to the onset of severe disease in horses; and, 2) by examining host and microbiota data simultaneously we aim to elucidate the mechanisms of host-microbiota interactions in the context of health and disease. Ultimately, we aim to use this approach to identify specific pathway by which the host and microbiota interact so that this critically important interaction can be targeted therapeutically.
In order to achieve our goals, we will utilize a reversible model of GI inflammation with which we have extensive experience. We will induce GI inflammation with the non-steroidal anti-inflammatory drug (NSAID) phenylbutazone and noninvasively interrogate the response and response of the microbiota. Importantly, we will collect samples sequentially both before and after induction of inflammation in order to gain predictive and diagnostic information about GI inflammation in horses. This approach will have broad application to many equine intestinal disorders and will provide the much needed mechanistic insight into disease development and progression, thereby enabling us to develop effective prevention and treatment strategies for equine GI disease.
The total cost of this study is $46,756 in 2019 and $45,814 in 2020. The EMRC recommends $12,000 for funding this study.
Paraoxonase-1 Activity as a Marker for Diagnosis of Equine Metabolic Syndrome Gabriele Rossi, DVM, Ph.D., DECVCP Murdoch University
Summary: Researchers will investigate a new laboratory test to improve diagnosis of equine metabolic syndrome, a metabolic and hormonal disorder in horses.
Description: Equine metabolic syndrome (EMS) is characterized by abnormal insulin regulation, obesity, and susceptibility to laminitis. EMS is challenging to diagnose since laboratory tests fail to distinguish EMS from other common equine diseases. Human metabolic syndrome (HMS) shares similar laboratory features to EMS and a new serum biomarker has been proposed in human medicine to improve the diagnosis of HMS. Researchers will investigate if this new HMS test also can provide an accurate diagnosis for horses with EMS. A new efficient and cost-effective EMS test will help veterinarians better diagnose and manage this complex disease in horses.
The total cost of this study is $9,355. The EMRC recommends $9,355 to fund this study.
Cell-mediated immunogenicity and MHC expression regulation of TGF-beta2-treated mesenchymal stem cells for improved clinical use in the horse. Lauren V Schnabel, DVM, Ph.D., DACVS, DACVSMR North Carolina State University
Summary: Researchers will manipulate the expression of immune markers on stem cells to develop safer and more effective therapies for horses with musculoskeletal injuries.
Description: Stem cell therapies have the potential to improve the outcome of potentially severe and life-ending musculoskeletal injuries in horses. However, sometimes the recipients immune system will destroy transplanted stem cells if the immune system perceives the introduced cells as foreign. To improve stem cell treatment success, researchers will examine if a novel cell culture treatment can be used to prevent the immune system from destroying donor stem cells. This study will help researchers better understand the cellular regulation of the molecules that initiate immune responses and advance the development of convenient and effective off-the-shelf stem cell therapy.
The total cost of this study is $131,479. The EMRC recommends $12,000 to fund this study. This is the second year that we are recommending funding this 3 year study.
Stephen Teichman Study
The goal is to determine the effects of front shoe surface modifications in the sport horse on the duration of breakover. We discussed and agreed to support this study during the May BOG conference call providing the publishing and professional fees were researched and found to be reasonable, which they were.
The total cost of this study is $9,640. The EMRC recommends USEA to provide $4,820 and an additional $4,820 is to be contributed by other donors.
This brings the total recommended research total to $38,175, leaving $1,406 of use at another time.
For an update on studies previously selected for funding by the USEA Equine Medical Research Committee, click here. To learn more about how the Equine Medical Research Fund got started, click here. For additional information about the Fund, click here.
- Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury - BMC Blogs Network - May 29th, 2020
- Startup targets glioblastoma tumors with CAR-T therapy - FierceBiotech - May 29th, 2020
- Coronavirus (COVID-19) Business Impact Stem Cell Therapy Market Size Analysis 2019-2027 - Cole of Duty - May 29th, 2020
- COVID-19: Responding to the business impacts of Allogeneic Stem Cell Therapy Revenue, Opportunity, Forecast and Value Chain 2019-2020 - Cole of Duty - May 29th, 2020
- AUGUSTMAN Grooming Awards 2020 Part IV: Best Head-To-Toe Treatment Services For Gentlemen - AUGUSTMAN - May 29th, 2020
- On the Origins of Modern Biology and the Fantastic: Part 18 Nalo Hopkinson and Stem Cell Research - tor.com - May 29th, 2020
- Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical... - May 28th, 2020
- Myeloma cells shift osteoblastogenesis to adipogenesis by inhibiting the ubiquitin ligase MURF1 in mesenchymal stem cells - Science - May 28th, 2020
- Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis - GlobeNewswire - May 28th, 2020
- COVID-19 Impact on Global Cancer Stem Cell Therapy Market 2020: Industry Trends, Size, Share, Growth Applications, SWOT Analysis by Top Key Players... - May 28th, 2020
- ViaCyte to Present at the Jefferies Virtual Healthcare Conference - Monterey County Weekly - May 28th, 2020
- AdventHealth launches first-of-its-kind immunotherapy treatment, clinical trial for specific blood cancer patients - The Daily Ridge - May 28th, 2020
- Gamida looks to build out cell therapy infrastructure - Bioprocess Insider - BioProcess Insider - May 28th, 2020
- Rheumatoid Arthritis Stem Cell Therapy Market to Register Substantial Expansion by Fact.MR - The Cloud Tribune - May 28th, 2020
- On the Origins of Modern Biology and the Fantastic: Part 19 Nalo Hopkinson and Stem Cell Research - tor.com - May 28th, 2020
- Stem Cell Alopecia Treatment Market Growth Analysis by Size, Top Companies, Supply Demand, Trends, Demand, Overview and Forecast to 2026 - Cole of... - May 28th, 2020
- Monocyte-derived multipotent cell delivered programmed therapeutics to reverse idiopathic pulmonary fibrosis - Science Advances - May 28th, 2020
- EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer | More News | News Channels -... - May 28th, 2020
- Stem Cell Therapy Industry Global Market Research and Analysis 2020-2026 - Cole of Duty - May 28th, 2020
- Coronavirus business impact: Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Extracts Circulating Tumor Cells (CTCs) and Cancer... - May 28th, 2020
- Clinical Outcomes Using RYONCIL (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles... - May 26th, 2020
- Stem Cell Therapy Market 2020: Consumption, Trends, Growth, Types,Industrial Applications, Leading Companies & Forecast till 2026 - Jewish Life... - May 26th, 2020
- Silver Nanoparticle-Induced Apoptosis in ARPE-19 Cells Is Inhibited by | IJN - Dove Medical Press - May 26th, 2020
- Adipose Derived Stem Cell Therapy Market (Impact of COVID-19) Sales To 2026 Anticipeted By Key Players - Surfacing Magazine - May 26th, 2020
- Life celebrates 20th anniversary during English Tourism Week - North East Times - May 26th, 2020
- Stem Cell Therapy Market To Boom In Near Future By 2027 Scrutinized In New Research - News Distinct - May 26th, 2020
- Retinitis Pigmentosa Treatment Market : Growth factor with key drivers, industry research, regional forecast - Jewish Life News - May 26th, 2020
- COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 - Jewish Life News - May 26th, 2020
- Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 - Cole of Duty - May 26th, 2020
- COVID-19 treatments are a better bet than a vaccine - Stockhead - May 26th, 2020
- Autologous Cell Therapy Market 2020 Competition by Manufacturers, Concentration Rate, Production Volume, Price|BioTime, Inc., BrainStorm Cell... - May 26th, 2020
- Mesoblast : 3 Articles on RYONCIL GvHD Trial Results Published in BBMT - Marketscreener.com - May 25th, 2020
- Will there still be massage treatments? What the future of luxury spas looks like - Telegraph.co.uk - May 25th, 2020
- The Week Ahead In Biotech: ASCO Presentations In The Spotlight - Benzinga - May 25th, 2020
- Lawyer celebrates 40 years with Blythe Liggins after first day hiccup - Leamington Observer - May 24th, 2020
- Stem Cell Banking Market Market Share, Size 2020| Emerging Rapidly with Global Latest Trends, Growth, Revenue, Demand and Forecast to 2027 - Cole of... - May 24th, 2020
- Covid-19 Impact on Cancer Stem Cell Therapy Market Trends Analysis, Top Manufacturers, Shares, Growth Opportunities, Statistics & Forecast to 2026... - May 24th, 2020
- What is a cytokine storm? And why is its prevention key to treating Covid-19? - Scroll.in - May 24th, 2020
- Covid-19 Impact On Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 : Industry Trends, Size, Growth, Swot Analysis By Top Key... - May 24th, 2020
- Restoring vision to the blind - Science Magazine - May 24th, 2020
- Ontario Announces First Phase of Research Projects to Fight COVID-19 - Government of Ontario News - May 24th, 2020
- Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Pulmonology Advisor - May 23rd, 2020
- World coronavirus Dispatch: Animal Stem Cell Therapy Market Size, Share, Statistics, Demand and Revenue; Forecast To 2025 - 3rd Watch News - May 23rd, 2020
- Cells for Cells and Austrianova announce publication on novel method to produce stem cell exosomes - BioSpace - May 23rd, 2020
- The Economic Impact of Coronavirus on Platelet Rich Plasma and Stem Cell Alopecia Treatment Market : In-depth study on Industry Size and Analysis on... - May 23rd, 2020
- World coronavirus Dispatch: Rheumatoid Arthritis Stem Cell Therapy market to witness robust revenue growth between 2018 to 2028 - Cole of Duty - May 23rd, 2020
- Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - TheStreet - May 23rd, 2020
- Animal Stem Cell Therapy Market: Overview, Opportunities, Analysis of Features, Benefits, Manufacturing Cost and Forecast To 2025 - Cole of Duty - May 23rd, 2020
- Looking toward the Future of Cell & Gene Therapies - Genetic Engineering & Biotechnology News - May 22nd, 2020
- NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Yahoo... - May 22nd, 2020
- Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and... - May 22nd, 2020
- Blocking the deadly cytokine storm is a vital weapon for treating COVID-19 - The Conversation US - May 22nd, 2020
- Analysis on Impact of COVID-19-Stem Cell Therapy Market 2020-2024 | Increase in Awareness of Stem Cell Therapy to Boost Growth | Technavio - Business... - May 19th, 2020
- NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients - Business... - May 19th, 2020
- Stem Cell Therapy Improved Quality of Life in Patients with Microvascular Dysfunction - Diagnostic and Interventional Cardiology - May 19th, 2020
- Can stem cell therapy help - Greater Kashmir - May 19th, 2020
- Family needs to raise 40k towards potentially life-changing treatment for mum with MS - Coventry Telegraph - May 19th, 2020
- Interim Results of Phase I Study Confirms Safety with Early Signs of Efficacy for TRPH-222 in NHL - OncoZine - May 19th, 2020
- Stem Cell Treatments Market Report, History and Forecast 2015-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application - Express... - May 19th, 2020
- Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19 - Monthly Prescribing Reference - May 17th, 2020
- Coronavirus: Emirati dentist who received stem cell therapy doing well - Gulf News - May 17th, 2020
- Stem Cell Therapy Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 - Cole of Duty - May 17th, 2020
- Outcomes of Hematopoietic Stem Cell Transplantation in Children With Diamond-Blackfan Anemia - Hematology Advisor - May 17th, 2020
- Venetoclax May Play Role as Salvage Therapy in Multiply Relapsed MCL - Targeted Oncology - May 17th, 2020
- The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows - Benzinga - May 17th, 2020
- GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR)... - May 17th, 2020
- Michael Hiltzik: Don't be taken in by stem cell firms offering unsubstantiated therapies for COVID-19 - Rome News-Tribune - May 15th, 2020
- Mike Tyson lifts lid on training regime and stem-cell therapy ahead of comeback - Metro.co.uk - May 15th, 2020
- Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire - May 15th, 2020
- Mum's brutal stem cell treatment has 'all been worth it' as she enjoys time with family - Grimsby Live - May 15th, 2020
- Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment... - May 15th, 2020
- Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock - Motley Fool - May 15th, 2020
- Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Re | CEOR - Dove Medical Press - May 15th, 2020
- Mesoblast raises $138m from investors on hopes for COVID-19 treatment - Sydney Morning Herald - May 15th, 2020
- Group of Genes Have Altered Expression in Autism - Technology Networks - May 15th, 2020
- SENECA BIOPHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - marketscreener.com - May 15th, 2020
- Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 15th, 2020
- Cardio Stem Cell Therapy Used to Treat Critically Ill Covid-19 Patients - Physician's Weekly - May 14th, 2020
- Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131 - GlobeNewswire - May 14th, 2020
- Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a... - May 14th, 2020